246 related articles for article (PubMed ID: 25726554)
1. Long-term experience in the treatment of α1-antitrypsin deficiency: 25 years of augmentation therapy.
Teschler H
Eur Respir Rev; 2015 Mar; 24(135):46-51. PubMed ID: 25726554
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and treatment of lung disease associated with alpha one-antitrypsin deficiency: A position statement from the Thoracic Society of Australia and New Zealand.
Dummer J; Dobler CC; Holmes M; Chambers D; Yang IA; Parkin L; Smith S; Wark P; Dev A; Hodge S; Dabscheck E; Gooi J; Samuel S; Knowles S; Holland AE
Respirology; 2020 Mar; 25(3):321-335. PubMed ID: 32030868
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.
Blanco I; Lara B; de Serres F
Orphanet J Rare Dis; 2011 Apr; 6():14. PubMed ID: 21486454
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
6. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency.
O'Brien ME; Fee L; Browne N; Carroll TP; Meleady P; Henry M; McQuillan K; Murphy MP; Logan M; McCarthy C; McElvaney OJ; Reeves EP; McElvaney NG
Thorax; 2020 Apr; 75(4):321-330. PubMed ID: 31959730
[TBL] [Abstract][Full Text] [Related]
7. Alpha1-antitrypsin deficiency: forgotten etiology.
Kaplan A; Cosentino L
Can Fam Physician; 2010 Jan; 56(1):19-24. PubMed ID: 20090075
[TBL] [Abstract][Full Text] [Related]
8. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
[TBL] [Abstract][Full Text] [Related]
9. Alpha-1 antitrypsin augmentation therapy.
Wewers MD; Crystal RG
COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
[TBL] [Abstract][Full Text] [Related]
10. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
11. α1-Antitrypsin Deficiency.
Hatipoğlu U; Stoller JK
Clin Chest Med; 2016 Sep; 37(3):487-504. PubMed ID: 27514595
[TBL] [Abstract][Full Text] [Related]
12. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG;
Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936
[TBL] [Abstract][Full Text] [Related]
13. Augmentation therapy with alpha1-antitrypsin: novel perspectives.
Sabina J; Tobias W
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):90-8. PubMed ID: 23987997
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1 antitrypsin: now available, but do we need it?
Russi EW
Swiss Med Wkly; 2008 Apr; 138(13-14):191-6. PubMed ID: 18389391
[TBL] [Abstract][Full Text] [Related]
15. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.
Barjaktarevic I; Miravitlles M
BMC Pulm Med; 2021 Mar; 21(1):99. PubMed ID: 33757485
[TBL] [Abstract][Full Text] [Related]
16. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency.
Tirado-Conde G; Lara B; Miravitlles M
Ther Adv Respir Dis; 2008 Feb; 2(1):13-21. PubMed ID: 19124355
[TBL] [Abstract][Full Text] [Related]
17. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
18. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation.
Ma S; Lin YY; He J; Rouhani FN; Brantly M; Turino GM
COPD; 2013 Aug; 10(4):473-81. PubMed ID: 23560990
[TBL] [Abstract][Full Text] [Related]
19. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
[TBL] [Abstract][Full Text] [Related]
20. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
Schmid ST; Koepke J; Dresel M; Hattesohl A; Frenzel E; Perez J; Lomas DA; Miranda E; Greulich T; Noeske S; Wencker M; Teschler H; Vogelmeier C; Janciauskiene S; Koczulla AR
Int J Chron Obstruct Pulmon Dis; 2012; 7():687-96. PubMed ID: 23055718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
